GlucoLight Corporation Raises Third Tranche Of ''c'' Round Financing
BETHLEHEM, Pa.--(BUSINESS WIRE)--GlucoLight Corporation, a development-stage company focused on non-invasive, continuous blood glucose monitoring, today announced the closing of the third
Read Full Article
Related Articles
- Pioneering Cancer treatment technology backed by London Seed Capital also categorized in Funding
- GlucoLight Corporation Raises Second Tranche of ''c'' Round Financing also categorized in Funding
- Bioptigen Receives FDA Clearance and Two Phase II SBIR Awards; Company to Exhibit at Major Technology Conference also categorized in Funding
- OCTANe Foundation for Innovation Grants $20,000 Innovation Award also published in businesswire.com
- OCT market to top $800 million by 2012 also categorized in Funding
- Lantis Laser Successfully Completes $2.5 Million Financing also categorized in Funding
- Method and apparatus for monitoring glucose levels in a biological tissue also mentions GlucoLight
- GlucoLight Corporation Raises Second Tranche of “c” Round Financing also published in businesswire.com
- Successful OCT imaging during cancer surgery also categorized in Funding
- Lantis Laser (LLSR) Successfully Completes $2.5 Million Financing also categorized in Funding
Login to comment.